Eli Lilly reported a 47.7% revenue increase to $22.97 billion in Q2 2026, surpassing expectations and raising its full-year revenue guidance to $85-$87 billion. The company’s stock trades near $1,185 with a 24/7 Wall St. price target of $1,401, suggesting an 18% upside. Key drivers include strong sales of GLP-1 drugs like Mounjaro and Zepbound, FDA approval of Onswik insulin, and promising retatrutide trial results. While competition and price declines pose risks, Lilly's rapid growth and pipeline advancements position it as a potential $2 trillion drugmaker in the coming years.
Eli Lilly's market cap on Pluang reached $1.02 trillion as of Oct 02, 2026 20:11 WIB, highlighting its stature near the $2 trillion mark discussed in the article. The stock price stood at USD 1,151.75 with a minimal 1-day change of +0.03%, showing stable investor interest despite the article's noted price target of $1,401. Pluang data also reveals a balanced order activity with 52% Sell and 48% Buy, reflecting a cautious but engaged market for Eli Lilly shares.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
